INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined mushrooms. Clear

Pooled results from many studies on one question.

3 studies

2021 / Prospective cohort study and meta-analysis of prospective cohort studies

In a meta-analysis of prospective cohort studies, mushroom intake was linked to a lower risk of all-cause mortality.

Researchers analyzed 30,378 NHANES participants over a mean follow-up of 6.7 years and conducted a meta-analysis combining these data with four other prospective cohort studies (totaling 601,893 individuals). In NHANES, mushroom consumption showed a non-significant association with all-cause mortality after multivariable adjustments (adjusted HR 0.84; 95% CI: 0.67-1.06; 2,855 deaths). However, the meta-analysis found that mushroom consumption was associated with a lower risk of all-cause mortality (pooled risk ratio 0.94; 95% CI: 0.91, 0.98).

Shows an association, not proof of cause and effect.

Ba DM, Gao X, Al-Shaar L, et al. Nutr J, 2021. PMID 34548082

2019 / Systematic review of clinical studies

Clinical studies link mushroom-derived lentinan to benefits during conventional cancer therapy.

A systematic review evaluated 135 clinical studies from China comprising 9,474 cancer treatment cases involving the shiitake polysaccharide lentinan. Most cases involved lung (3,469), gastric (3,039), or colorectal (1,646) malignancies. Across evaluated reports, lentinan use was linked to better quality of life and greater efficacy of concurrent chemotherapy or radiation treatment.

Zhang M, Zhang Y, Zhang L, et al. Prog Mol Biol Transl Sci, 2019. PMID 31030752

2012 / Meta-analysis of randomized controlled trials

Reishi mushroom as an adjunct to cancer therapy showed potential immune and response benefits

A meta-analysis of five randomized trials examined Ganoderma lucidum in cancer care. Combining the mushroom with chemotherapy or radiotherapy increased the likelihood of a positive response compared to conventional therapy alone (RR 1.50, 95% CI 0.90 to 2.51). Furthermore, supplementation raised CD3, CD4, and CD8 percentages by 3.91%, 3.05%, and 2.02%, while quality of life was relatively improved in four studies.

Jin X, Ruiz Beguerie J, Sze DM, et al. Cochrane Database Syst Rev, 2012. PMID 22696372